Completed PHASE2 INTERVENTIONAL 1-arm NCT00110266

Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients

An Open Label, Safety and Tolerability Study of Deferasirox for Treatment of Transfusional Iron Overload in Low-risk and INT-1, Myelodysplastic Patients Using Serum Ferritin Monitoring

Sponsor: Novartis Pharmaceuticals

Conditions Iron Overload Myelodysplastic Syndrome

Interventions Deferasirox

Updated 8 times since 2017 Last updated: Jul 21, 2021 Started: Jul 25, 2005 Primary completion: Mar 28, 2008 Completion: Mar 28, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Iron Overload and Myelodysplastic Syndrome, this trial is completed. The trial is conducted by Novartis Pharmaceuticals and has accumulated 8 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Sep 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Sep 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jul 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Alexandria, United States , Arlington, United States , Asheville, United States , Atlanta, United States , Aurora, United States , Baltimore, United States , Birmingham, United States , Buffalo, United States , Chicago, United States and 32 more locations